Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy

Aisha V. Sauer, Henner Morbach, Immacolata Brigida, Yen Shing Ng, Alessandro Aiuti, Eric Meffre

Research output: Contribution to journalArticle

Abstract

Adenosine deaminase (ADA) gene defects are among the most common causes of SCID. Restoration of purine metabolism and immune functions can be achieved by enzyme replacement therapy, or more effectively by bone marrow transplant or HSC gene therapy (HSC-GT). However, autoimmune complications and autoantibody production, including anti-nuclear antibodies (ANAs), frequently occur in ADA-SCID patients after treatment. To assess whether ADA deficiency affects the establishment of B cell tolerance, we tested the reactivity of recombinant antibodies isolated from single B cells of ADA-SCID patients before and after HSC-GT. We found that before HSC-GT, new emigrant/transitional and mature naive B cells from ADA-SCID patients contained more autoreactive and ANA-expressing clones, indicative of defective central and peripheral B cell tolerance checkpoints. We further observed impaired B cell receptor (BCR) and TLR functions in B cells after ADA inhibition, which may underlie the defects in B cell tolerance. Strikingly, after HSC-GT, ADA-SCID patients displayed quasi-normal early B cell tolerance checkpoints, as evidenced by restored removal of developing autoreactive and ANA-expressing B cells. Hence, ADA plays an essential role in controlling autoreactive B cell counterselection by regulating BCR and TLR functions.

Original languageEnglish
Pages (from-to)2141-2152
Number of pages12
JournalJournal of Clinical Investigation
Volume122
Issue number6
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Genetic Therapy
B-Lymphocytes
Adenosine Deaminase
Anti-Idiotypic Antibodies
Severe combined immunodeficiency due to adenosine deaminase deficiency
Enzyme Replacement Therapy
Autoantibodies
Clone Cells
Bone Marrow
Transplants
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. / Sauer, Aisha V.; Morbach, Henner; Brigida, Immacolata; Ng, Yen Shing; Aiuti, Alessandro; Meffre, Eric.

In: Journal of Clinical Investigation, Vol. 122, No. 6, 01.06.2012, p. 2141-2152.

Research output: Contribution to journalArticle

Sauer, Aisha V. ; Morbach, Henner ; Brigida, Immacolata ; Ng, Yen Shing ; Aiuti, Alessandro ; Meffre, Eric. / Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. In: Journal of Clinical Investigation. 2012 ; Vol. 122, No. 6. pp. 2141-2152.
@article{851c694b8afb4f8ca656e092ab9c19b0,
title = "Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy",
abstract = "Adenosine deaminase (ADA) gene defects are among the most common causes of SCID. Restoration of purine metabolism and immune functions can be achieved by enzyme replacement therapy, or more effectively by bone marrow transplant or HSC gene therapy (HSC-GT). However, autoimmune complications and autoantibody production, including anti-nuclear antibodies (ANAs), frequently occur in ADA-SCID patients after treatment. To assess whether ADA deficiency affects the establishment of B cell tolerance, we tested the reactivity of recombinant antibodies isolated from single B cells of ADA-SCID patients before and after HSC-GT. We found that before HSC-GT, new emigrant/transitional and mature naive B cells from ADA-SCID patients contained more autoreactive and ANA-expressing clones, indicative of defective central and peripheral B cell tolerance checkpoints. We further observed impaired B cell receptor (BCR) and TLR functions in B cells after ADA inhibition, which may underlie the defects in B cell tolerance. Strikingly, after HSC-GT, ADA-SCID patients displayed quasi-normal early B cell tolerance checkpoints, as evidenced by restored removal of developing autoreactive and ANA-expressing B cells. Hence, ADA plays an essential role in controlling autoreactive B cell counterselection by regulating BCR and TLR functions.",
author = "Sauer, {Aisha V.} and Henner Morbach and Immacolata Brigida and Ng, {Yen Shing} and Alessandro Aiuti and Eric Meffre",
year = "2012",
month = "6",
day = "1",
doi = "10.1172/JCI61788",
language = "English",
volume = "122",
pages = "2141--2152",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy

AU - Sauer, Aisha V.

AU - Morbach, Henner

AU - Brigida, Immacolata

AU - Ng, Yen Shing

AU - Aiuti, Alessandro

AU - Meffre, Eric

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Adenosine deaminase (ADA) gene defects are among the most common causes of SCID. Restoration of purine metabolism and immune functions can be achieved by enzyme replacement therapy, or more effectively by bone marrow transplant or HSC gene therapy (HSC-GT). However, autoimmune complications and autoantibody production, including anti-nuclear antibodies (ANAs), frequently occur in ADA-SCID patients after treatment. To assess whether ADA deficiency affects the establishment of B cell tolerance, we tested the reactivity of recombinant antibodies isolated from single B cells of ADA-SCID patients before and after HSC-GT. We found that before HSC-GT, new emigrant/transitional and mature naive B cells from ADA-SCID patients contained more autoreactive and ANA-expressing clones, indicative of defective central and peripheral B cell tolerance checkpoints. We further observed impaired B cell receptor (BCR) and TLR functions in B cells after ADA inhibition, which may underlie the defects in B cell tolerance. Strikingly, after HSC-GT, ADA-SCID patients displayed quasi-normal early B cell tolerance checkpoints, as evidenced by restored removal of developing autoreactive and ANA-expressing B cells. Hence, ADA plays an essential role in controlling autoreactive B cell counterselection by regulating BCR and TLR functions.

AB - Adenosine deaminase (ADA) gene defects are among the most common causes of SCID. Restoration of purine metabolism and immune functions can be achieved by enzyme replacement therapy, or more effectively by bone marrow transplant or HSC gene therapy (HSC-GT). However, autoimmune complications and autoantibody production, including anti-nuclear antibodies (ANAs), frequently occur in ADA-SCID patients after treatment. To assess whether ADA deficiency affects the establishment of B cell tolerance, we tested the reactivity of recombinant antibodies isolated from single B cells of ADA-SCID patients before and after HSC-GT. We found that before HSC-GT, new emigrant/transitional and mature naive B cells from ADA-SCID patients contained more autoreactive and ANA-expressing clones, indicative of defective central and peripheral B cell tolerance checkpoints. We further observed impaired B cell receptor (BCR) and TLR functions in B cells after ADA inhibition, which may underlie the defects in B cell tolerance. Strikingly, after HSC-GT, ADA-SCID patients displayed quasi-normal early B cell tolerance checkpoints, as evidenced by restored removal of developing autoreactive and ANA-expressing B cells. Hence, ADA plays an essential role in controlling autoreactive B cell counterselection by regulating BCR and TLR functions.

UR - http://www.scopus.com/inward/record.url?scp=84861833417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861833417&partnerID=8YFLogxK

U2 - 10.1172/JCI61788

DO - 10.1172/JCI61788

M3 - Article

C2 - 22622038

AN - SCOPUS:84861833417

VL - 122

SP - 2141

EP - 2152

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -